Trust Signals
Key Takeaways
- Tesamorelin is the only cutting peptide with FDA approval (for HIV lipodystrophy) and the strongest human RCT data for measurable fat reduction.
- Most GH secretagogues (Ipamorelin, CJC-1295) raise growth hormone measurably in humans but direct body-composition RCT evidence in healthy individuals is limited.
- AOD-9604 was designed to avoid raising IGF-1, making it mechanistically distinct from other GH-derived peptides, but large human trials have not confirmed superior fat loss outcomes.
- Semaglutide outperforms every cutting peptide in head-to-head evidence volume; peptides are not a superior alternative for total body weight loss.
- Purity of research-grade peptides is unverified by any regulatory body; acetate salt impurities and sequence errors are documented quality issues in third-party testing.
What Are the Best Cutting Peptides?
Table of Contents
- Evidence Ledger: All Major Claims Graded
- How Do Cutting Peptides Actually Work? Mechanism With Real Numbers
- The Five Best Cutting Peptides Ranked
- What Most Pages Get Wrong About Cutting Peptides
- CJC-1295 With DAC vs. Without: Why the Chemistry Matters
- Honest Head-to-Head: Cutting Peptides vs. Real Alternatives
- Dosing and Protocol Table
- Operational and Label Literacy: How to Judge a Product
- What Are the Real Risks?
- FAQ
- Sources
Evidence Ledger: All Major Claims Graded
| Claim | Best Evidence Available | Effect Direction | Confidence |
|---|---|---|---|
| Tesamorelin reduces trunk fat in HIV lipodystrophy | Multiple human RCTs (Falutz et al., 2007, 2010) | Positive (significant reduction) | High |
| Tesamorelin reduces trunk fat in non-HIV healthy adults | Limited off-label use data, no large RCT | Plausible, unconfirmed magnitude | Low |
| Ipamorelin raises GH in humans | Small human pharmacokinetic studies | Positive | Moderate |
| CJC-1295 raises GH and IGF-1 in humans | Sackmann-Sala et al., 2009 (human RCT, n=21) | Positive | Moderate |
| CJC-1295 or Ipamorelin improves body composition in healthy adults | Animal and mechanistic data primarily | Plausible, not robustly confirmed | Low |
| AOD-9604 stimulates lipolysis without raising IGF-1 | Animal studies and small human pilot data | Positive in animal models | Low to Moderate |
| AOD-9604 produces clinically meaningful fat loss in humans | Phase 2 trials (Metabolic Pharmaceuticals; results mixed) | Inconsistent across doses | Low |
| BPC-157 improves body composition | Animal studies only | Positive in rodents | Very Low |
| GH secretagogue stacking (CJC + Ipamorelin) synergistic | Receptor pharmacology reasoning, limited human data | Mechanistically plausible | Low |
| GHRP class causes receptor desensitization with continuous use | Animal receptor studies | Positive in animal models | Low (human timeline unclear) |
How Do Cutting Peptides Actually Work? Mechanism With Real Numbers
The term "cutting peptide" covers at least three distinct mechanisms. Understanding which one applies to each compound prevents misplaced expectations.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →GHRH analogs (Tesamorelin, CJC-1295): These bind the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs. This triggers cyclic AMP signaling and pulsatile GH secretion. Sackmann-Sala et al. (2009) showed that a single 30 mcg/kg dose of CJC-1295 with DAC elevated mean serum IGF-1 by roughly 30 to 40% over several days. Elevated GH activates hormone-sensitive lipase in adipocytes via JAK2-STAT5b signaling, increasing fatty acid mobilization from triglyceride stores. The honest caveat: elevated GH and IGF-1 in a lab value does not automatically equal proportional adipose tissue loss in a real human eating a caloric surplus.
Ghrelin receptor agonists (Ipamorelin, GHRP-2, GHRP-6): These bind the GHS-R1a receptor. Ipamorelin is selective for GH release with relatively low effect on cortisol and prolactin compared to older GHRPs like GHRP-6, which is why it is preferred in cutting contexts. Peak GH elevation after Ipamorelin injection occurs within roughly 15 to 30 minutes in human pharmacokinetic data. The ghrelin receptor pathway is separate from the GHRH pathway, which is the mechanistic rationale for stacking Ipamorelin with CJC-1295.
GH fragment analogs (AOD-9604): AOD-9604 is a synthetic peptide corresponding to amino acids 177 to 191 of the GH molecule. This C-terminal fragment was theorized to contain the lipolytic activity of GH while lacking the growth-promoting domain responsible for IGF-1 elevation. Animal studies showed it stimulated lipolysis in adipocytes. Phase 2 human trials run by Metabolic Pharmaceuticals tested multiple oral doses; results were inconsistent and did not support a clear dose-response relationship for fat loss. The program did not advance to Phase 3. What this does NOT prove: that injectable AOD-9604 at doses used in fitness contexts will produce the fat loss seen in favorable animal models.
The Five Best Cutting Peptides Ranked
1. Tesamorelin. Only cutting peptide with genuine Phase 3 RCT data and an FDA approval on record. Falutz et al. (2007, NEJM) demonstrated statistically significant trunk fat reduction versus placebo over 26 weeks in HIV-positive patients with lipodystrophy. The extrapolation to healthy individuals is plausible but not proven. Requires daily subcutaneous injection.
2. Ipamorelin + CJC-1295 (without DAC / Mod GRF 1-29). The most widely used stack in fitness contexts. Human data confirm GH elevation. Body-composition data in healthy adults are sparse but mechanistically the pathway is sound. The pulsatile dosing strategy (pre-sleep injection) attempts to mimic physiologic GH release patterns.
3. CJC-1295 with DAC. Longer half-life (approximately 8 days due to albumin binding) means less frequent injection but produces a sustained GH bleed rather than a pulse. Some practitioners argue this is less physiologic and carries more potential for receptor downregulation. Limited direct comparison to pulsatile protocols in humans.
4. AOD-9604. Mechanistically interesting for avoiding IGF-1 elevation. Phase 2 human data exist but are not decisive. Most users inject it subcutaneously despite the original pharmaceutical development being oral. No injectable-specific human trials are publicly available with robust data.
5. GHRP-6 / GHRP-2. Older generation GHRPs with more human pharmacokinetic data than Ipamorelin but a significantly worse side-effect profile including notable hunger stimulation (GHRP-6) and cortisol elevation, both counterproductive in a cutting context. Listed here for completeness, not as a recommendation over Ipamorelin.
What Most Pages Get Wrong About Cutting Peptides
CJC-1295 With DAC vs. Without: Why the Chemistry Matters
CJC-1295 without DAC (Mod GRF 1-29) is a 29-amino-acid GHRH analog. Its short half-life, approximately 30 minutes in vivo, is due to rapid cleavage by dipeptidyl peptidase-4 (DPP-IV) at the Ala-2 position, and by other circulating proteases. This short window produces a sharp GH pulse that resembles natural pulsatile secretion, which is considered favorable by some practitioners for preserving receptor sensitivity.
CJC-1295 with DAC adds a Drug Affinity Complex, specifically a maleimidoproprionic acid-lysine linker that forms a covalent thioether bond with the cysteine-34 residue of serum albumin. This bond is stable enough to extend half-life to approximately 6 to 8 days based on the data from Jetté et al. (2005) and subsequent pharmacokinetic modeling. The result is continuous rather than pulsatile GH elevation.
Why does this matter practically? Continuous GH exposure differs physiologically from pulsatile. The pituitary naturally releases GH in pulses (primarily during slow-wave sleep). Mimicking this pulse structure is the rationale for timed nighttime injections of short-acting secretagogues. Sustained elevation may impair natural feedback loops over time, though the clinical significance of this at standard research doses has not been definitively established in humans. The rule of thumb to "use DAC for convenience, without DAC for physiology" has mechanistic logic but lacks a human RCT directly comparing body composition outcomes.
Honest Head-to-Head: Cutting Peptides vs. Real Alternatives
| Compound | Evidence for Fat Loss | Regulatory Status | Where Peptides WIN | Where Peptides LOSE |
|---|---|---|---|---|
| Tesamorelin | Strong RCT (specific population) | FDA approved (HIV lipodystrophy only) | Preserves lean mass | Off-label for healthy use; cost |
| Ipamorelin + CJC-1295 | Moderate (GH data), Low (body comp) | Not FDA approved; WADA banned | Potentially better sleep quality, recovery | No head-to-head fat loss vs. approved agents |
| Semaglutide (Wegovy) | Very High (Phase 3 RCTs, ~15% body weight) | FDA approved for obesity | Total weight loss magnitude | Peptides win on muscle preservation concern (theoretical) |
| Caffeine + Caloric Deficit | Moderate (multiple RCTs) | GRAS / legal | Cost, accessibility | Magnitude of effect smaller than GH-pathway peptides in theory |
| Prescription GH (Somatropin) | High (extensive human data) | FDA approved (specific indications) | Direct GH; cleaner PK | Peptides are safer side-effect profile at low doses; cost |
| AOD-9604 | Low (inconsistent Phase 2) | Not approved anywhere | No IGF-1 elevation theoretically | Phase 3 never completed; human injectable data absent |
The peptide world loses on total evidence weight. Acknowledging this is what gives the rest of the analysis credibility.
Dosing and Protocol Table
| Peptide | Common Research Dose | Frequency | Route | Cycle Length | Evidence Basis for Dose |
|---|---|---|---|---|---|
| Tesamorelin | 2 mg/day | Daily | Subcutaneous | 26+ weeks in trials | Phase 3 RCT protocol |
| Ipamorelin | 200 to 300 mcg | 1 to 3x daily (pre-sleep emphasized) | Subcutaneous | 8 to 12 weeks | Human PK studies; community extrapolation |
| CJC-1295 without DAC | 100 to 200 mcg | Co-administered with Ipamorelin | Subcutaneous | 8 to 12 weeks | Human GH studies; extrapolated |
| CJC-1295 with DAC | 1 to 2 mg | Once weekly or biweekly | Subcutaneous | 8 to 12 weeks | Albumin-binding PK data (Jetté 2005) |
| AOD-9604 | 250 to 300 mcg | Daily, fasted AM | Subcutaneous | Up to 12 weeks | Phase 2 oral trial doses adapted; injectable data absent |
| GHRP-6 | 100 mcg | 2 to 3x daily | Subcutaneous | 6 to 8 weeks | Human PK; not recommended for cutting due to hunger |
These doses reflect what appears in clinical literature and structured research contexts. They are not prescriptions. Dosing for off-label use should only occur under physician supervision.
Operational and Label Literacy: How to Judge a Product
Reading a COA (Certificate of Analysis). A legitimate peptide COA should include: HPLC purity (look for 98% or above for research-grade), mass spectrometry confirmation of the correct molecular weight, and ideally endotoxin testing. A COA from the peptide vendor's own in-house testing is meaningfully less trustworthy than one from an independent third-party lab. Confirm the lab name is real and searchable.
Reconstitution math example. If you have a 5 mg vial of Ipamorelin and you add 2.5 mL of bacteriostatic water: concentration = 5 mg divided by 2.5 mL = 2 mg/mL = 2000 mcg/mL. A 300 mcg dose requires 0.15 mL (15 units on a 100-unit insulin syringe). Getting this wrong by a factor of 10 is the most common user error, and errors in either direction carry real risk.
What a degraded vial looks like. After reconstitution: clear and colorless is correct. Cloudiness suggests contamination or protein aggregation. A yellow or brown tint indicates oxidation. Visible particulates mean do not use. Lyophilized powder should be white and cake-like. Granular or crystalline texture suggests the lyophilization failed or the vial was temperature abused in transit.
Acetate vs. TFA salt. Many research peptides are synthesized and purified as trifluoroacetate (TFA) salts. TFA has potential cytotoxic properties in cell studies. Pharmaceutical-grade peptides use acetate salt. When evaluating a supplier, ask whether the final product is TFA-free. A legitimate supplier will provide this information.
What Are the Real Risks?
Common and documented: Injection site redness or nodules, water retention (edema), transient numbness or tingling (paresthesia) associated with GH elevation, and elevated fasting glucose. The glucose effect is mechanistically expected since GH is counter-regulatory to insulin.
Theoretical and harder to quantify: Chronic GH and IGF-1 elevation is associated with accelerated cell proliferation in animal models. Whether short-course use at research doses in humans meaningfully increases cancer risk has not been established. The concern is taken seriously enough that GH and IGF-1 monitoring is recommended in clinical protocols using GH-stimulating agents.
Regulatory and legal: All GH secretagogues and GHRH analogs are on the WADA Prohibited List under class S2. Athletes subject to testing face serious sanctions. In the US, these compounds are not approved drugs for the indications discussed and are sold as research chemicals. Their legal status for human administration is ambiguous at best and prohibited in some contexts.
Purity risk: This is the underappreciated real-world risk. Without GMP manufacturing and independent verification, the compound you inject may not be what the label states. This is not a theoretical concern; independent testing programs have documented frequent quality failures in the research peptide market.
FAQ
Sources
- Falutz J, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370.
- Falutz J, et al. "Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation." AIDS. 2008;22(14):1719-1728.
- Sackmann-Sala L, et al. "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects." Growth Hormone and IGF Research. 2009;19(6):471-477.
- Jetté L, et al. "hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog." Endocrinology. 2005;146(7):3052-3058.
- Heffernan MA, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology. 2001;142(12):5182-5189.
- Metabolic Pharmaceuticals. AOD-9604 Phase 2 clinical trial data (summarized in public regulatory communications, 2001 to 2006).
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989-1002.
- World Anti-Doping Agency. Prohibited List 2024, Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA, 2024.
- FDA. "FDA approves Egrifta (tesamorelin) to reduce excess abdominal fat in HIV-infected patients." FDA News Release, November 10, 2010.
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561.
- Clark RG, et al. "A comparison of the effects of continuous and intermittent GH treatment on organ growth and lipid metabolism." Journal of Endocrinology. 1985;107(1):9-17. (Foundational pulsatile GH physiology reference.)